Meet the Editors
Jeffrey Laurence, MD, is a Professor of Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medical College, Attending Physician at New York Presbyterian Hospital, and Director of the Laboratory for AIDS Virus Research at those institutions. Additionally, he is Senior Scientist for Programs at amfAR, The Foundation for AIDS Research, co-founded by Dr. Mathilde Krim and Dame Elizabeth Taylor. Dr. Laurence’s current research focuses on mechanisms of HIV and HIV-treatment-associated cardiovascular and renal disease, and the thrombotic microangiopathies associated with complement activation and microvascular endothelial cell injury in HIV and other disorders.
Timothy Niewold, MD, is the Judith and Stewart Colton Professor of Medicine and Pathology at New York University School of Medicine. Dr. Niewold's laboratory is mapping the genetic factors that cause autoimmune diseases and exploring the ways in which genetic variations alter the human immune response to result in disease. Dr. Niewold has defined the ways in which interferon-alpha causes systemic lupus erythematosus and is currently interested in personalized medicine strategies in the treatment of autoimmune disease.
Brian D Hoit, MD, is a Professor Medicine and Physiology and Biophysics at Case Western Reserve University. Dr. Hoit’s research interests are focused on the clinical and mechanistic features of left ventricular hypertrophy, atrial function, and cardiovascular phenotyping in small animals. As one of the pioneers of murine echocardiography, he has lectured extensively on the topic, and has taught the technique to laboratories around the world.
Neal L. Weintraub, MD, is a Professor of Medicine at the Medical College of Georgia at Augusta University. Dr. Weintraub’s laboratory is focused on vascular biology research with emphasis on oxidative stress, inflammation, obesity, and stem cell biology. In particular, his work has advanced the understanding of the role of oxidative stress in the pathogenesis of abdominal aortic aneurysm disease. Dr. Weintraub’s clinical interests lie in vascular disease and heart failure.
Endocrinology and Metabolism
Lorraine Levitt Katz, MD, is a Professor in the Division of Endocrinology and Diabetes at the Children's Hospital of Philadelphia and Department of Pediatrics at the Perelman School of Medicine, University of Pennsylvania. She is co-director of the Center for Human Phenomic Science at the University of Pennsylvania. Dr. Katz is a pediatric endocrinologist with a particular interest in patient-oriented research relating to carbohydrate disorders and insulin-like growth factors. Independent clinical investigations focus on insulin secretion in pediatric type 2 diabetes mellitus, the pediatric metabolic syndrome (a "pre-diabetic" state), and the physiology of fasting.
Jay L. Goldstein, MD, is the Head of the Division of Gastroenterology and Executive Vice Chairman of Medicine at NorthShore University HealthSystem. He was formerly Professor of Medicine and Vice Head for Clinical Affairs in the Department of Medicine at the University of Illinois Medical Center at Chicago. In addition to his clinical responsibilities, Dr. Goldstein has been involved in research focusing on injury of the upper gastrointestinal tract. His clinical and research interests include the effects of nonsteroidal anti-inflammatory drugs in causing gastrointestinal injury, COX-2 specific inhibitors, gastroesophageal reflux disease, disease states associated with Helicobacter pylori, and outcomes research.
Martha Mims, MD, PhD, is Professor of Medicine and Section Chief of the Division of Hematology/Oncology at Baylor College of Medicine and Associate Director for Clinical Research at the Dan L Duncan Comprehensive Cancer Center. Dr. Mims' research interests are in genitourinary and hematologic malignancies. She is SWOG Principal Investigator for Baylor and a member of the Genitourinary and Leukemia committees at SWOG.
Greg Vercellotti, MD, is a Professor of Medicine in the Division of Hematology, Oncology, and Transplantation at the University of Minnesota. Dr. Vercellotti’s clinical interests range from coagulation and bleeding disorders, platelet disorders, red cell disorders, porphyria, bone marrow transplant, leukemia, lymphoma, and myeloma to immunologic deficiencies. His research focuses on inflammation and endothelial cell biology, the role of inflammation in vaso-occlusion in sickle cell anemia, the role of infection in atherosclerosis and vascular disease, and oxidative stress and vascular disease. Dr. Vercellotti discovered heme’s role in cell injury and the cytoprotective pathways that defend cells against heme-mediated oxidative damage. He applied these biological discoveries to understanding heme’s role in sickle cell disease (SCD), specifically proinflammatory vasculopathy, and developing therapeutic strategies that induce cytoprotective or inhibit inflammatory responses in SCD.
James L. Cook, MD, is Clinical Professor of Medicine at Loyola University Chicago. Dr. Cook's clinical expertise is in the diagnosis and treatment of patients with refractory, nontuberculous mycobacterial diseases. His basic research interests have included studies of interactions between the oncogenes of small DNA tumor viruses and the host cellular immune response to mammalian cells infected with, or neoplastically transformed by, these viruses. Recent studies have focused on adenovirus gene control of the host inflammatory responses and infection-induced lung immunopathogenesis. Laboratory bacteriology studies have included evaluation of the immunopathogenesis and novel drug discovery for potential agents of biowarfare, especially related to the immunopathogenesis of anthrax, mechanisms through which anthrax toxins affect mammalian cell function, and in vivo studies of anthrax infection and toxin activity.
James A. Shayman, MD, is Professor of Internal Medicine and Pharmacology and the Agnes C. And Frank D. McKay Professor of Medicine at the University of Michigan. Dr. Shayman’s research interests have focused on the study of lysosomal storage disorders, glycosphingolipid metabolism, the discovery of novel lysosomal hydrolases, and the development of small molecule inhibitors suitable for substrate reduction therapy. He holds numerous patents, including those for eliglustat tartrate the first stand-alone oral therapy for Gaucher disease type 1.
David Kamp, MD, is a Professor of Medicine in the Division of Pulmonary & Critical Care Medicine and Cell & Molecular Biology at Northwestern University Feinberg School of Medicine. Dr. Kamp’s research focus utilizes the asbestos paradigm for investigating the mechanisms underlying alveolar epithelial cell (AEC) injury that promote pulmonary fibrosis. The overall arching goal of his work centers on identifying novel epithelial cell targets that prevent lung fibrosis by mitigating mitochondrial dysfunction, mitochondrial (mt)-DNA damage, and apoptosis. His group established crucial functions for mitochondrial reactive oxygen species (ROS), sirtuin 3 (SIRT3) deficiency, and p53 activation in promoting AEC mt-DNA damage and intrinsic AEC apoptosis following asbestos exposure. Further, they showed that mitochondria-targeted 8-oxoguanine DNA glycosylase (mtOGG1), a DNA repair enzyme, has a non-canonical role of chaperoning mitochondrial aconitase (ACO-2), thereby preventing oxidant-induced AEC mtDNA damage and apoptosis.